Cardinal Health Boosts Investor Appeal with $5 Billion Buyback Authorization Alongside Strong Q4 Results

Cardinal Health (NYSE: CAH) delivered a standout fiscal fourth-quarter performance, with GAAP diluted earnings per share soaring 70 % to $1.70—while non‑GAAP EPS rose 40 % to $2.91—driven in part by a one‑time $0.31 benefit from IEEPA tariff refunds.

In response to the strong results, the company authorized a substantial $5 billion share buyback program and guided its fiscal 2027 adjusted EPS above long‑term targets, signaling robust confidence in its transformed business model.

These developments, both announced on August 11 in conjunction with the Q4 earnings release, triggered an uptick in the stock, pushing intraday trading to record highs among S&P 500 peers.

Q4 Performance and Capital Return Strategy

Cardinal Health’s Q4 fiscal 2026 report revealed a 70 % jump in GAAP EPS and a 40 % advance in non‑GAAP EPS—both markedly outperforming expectations. The earnings included a nonrecurring $0.31 gain from tariff refunds under IEEPA, underscoring exceptional operational strength across its core segments.

Following the strong earnings, the company launched a $5 billion share repurchase program, reflecting confidence in its capital allocation strategy and signaling shareholder value focus.

Fiscal 2027 Outlook

Alongside earnings details, Cardinal Health disclosed that its fiscal 2027 adjusted EPS guidance exceeds its previously stated long‑term targets, though the specific figure was not disclosed in secondary sources. This optimistic outlook indicates management’s expectation of continued strength as the company shifts toward higher‑margin services and specialty operations.

Investor Reaction and Stock Movement

According to market commentary, Cardinal Health shares climbed during intraday trading, reaching an all‑time high as investor attention zeroed in on the compelling earnings performance and forward guidance.

Why It Matters

These results mark a significant milestone in Cardinal Health’s strategic evolution—from a traditional distribution model toward a high‑margin, service‑driven healthcare infrastructure. The combination of exceptional Q4 execution, ambitious fiscal 2027 targets, and a large buyback program positions CAH as a distinctive value and growth proposition within the S&P 500.

Investors should continue monitoring actual adjusted guidance details when released and assess how the buyback execution pace aligns with the company’s balance sheet metrics.

Verified share price reference: As of September 1, 2026, CAH was trading at $239.35, reflecting a 1.06 % daily gain.